Soolantra worth $87m in the last year

Written by on July 18, 2017 in patents, Soolantra (Ivermectin Cream 1%) with 0 Comments


One thing we have learned from the news that Perrigo and Galderma are embarking on a patent dispute, is how successful Soolantra has been as a product.

Perrigo Confirms Patent Challenge For Generic Version Of Soolantra Cream, 1%

Soolantra (ivermectin) cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Annual market sales for the 12 months ending May 2017 were $87 million.

So sales of Soolantra are already approaching $100m a year.

[Update January 2018:] We now know that Soolantra has a $120m a year run rate from a further press release from Perrigo.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.